Leflok solution for infusions 5 mg/ml. 100 ml. №1 vial

Description

Leflok Composition
active substance: levofloxacin;

1 ml of solution contains levofloxacin hemihydrate in terms of levofloxacin 5 mg;

excipients: sodium chloride, diluted hydrochloric acid, sodium hydroxide, water for injection.

Leflok Dosage form
Solution for infusion.

Basic physical and chemical properties: clear liquid from yellow to yellow with a greenish tint.

Leflok Pharmacotherapeutic group
Antibacterial agents of the quinolone group. Fluoroquinolones. ATX code J01M A12.

Leflok Pharmacodynamics
Levofloxacin is a synthetic antibacterial drug from the group of fluoroquinolones, the S-enantiomer of the racemic mixture of the drug ofloxacin. As an antibacterial drug from the group of fluoroquinolones, levofloxacin acts on the DNA complex of DNA gyrase and topoisomerase IV. The main mechanism of resistance is a consequence of a mutation in the gyr-A genes.

In vitro cross-resistance exists between levofloxacin and other fluoroquinolones.

Indications
Leflok, solution for infusion, is prescribed for adults for the treatment of such infectious diseases caused by microorganisms sensitive to levofloxacin:

community-acquired pneumonia *;
complicated infections of the skin and soft tissues *;
acute pyelonephritis and complicated urinary tract infections;
chronic bacterial prostatitis;
pulmonary anthrax: post-exposure prophylaxis and radical treatment.
* regarding the above infectious diseases, levofloxacin should be prescribed only in cases of insufficient effectiveness of other antibacterial drugs, which are mainly used for the initial treatment of these infections.

Consideration should be given to official guidelines for the proper use of antibacterial agents.

Contraindications
Hypersensitivity to levofloxacin, other quinolones, to any component of the drug.
Adverse reactions from tendons after previous use of quinolones.
Epilepsy.
Children’s age (up to 18 years old).
The period of pregnancy or lactation.

Application features
Avoid the use of the drug in patients who have had serious adverse reactions in the past when using quinolones or fluoroquinolones. Treatment of these patients with levofloxacin should only be initiated in the absence of alternative treatment options and after a careful assessment of the benefit / risk.

Long-term, disabling and potentially irreversible serious adverse reactions

In very rare cases, patients receiving fluoroquinolones, regardless of age and existing risk factors, have reported long-term (over months or years) disabling and potentially irreversible serious adverse reactions that affect various, and sometimes several at once, body systems (musculoskeletal – motor, nervous, psyche and sense organs). The drug should be discontinued immediately after the first signs or symptoms of any serious adverse reaction appear and a doctor should be consulted.